Small Cap Gainers: KRYS, WDH, NRXP
2:35 pm Monday, November 29th, 2021
Krystal Biotech Inc (NASDAQ:KRYS) announced top-line results for its GEM-3 trial of VYJUVEK in patients with dystrophic Epidermolysis Bullosa. The primary endpoint of the study, which evaluated complete wound healing of topical VYJUVEK vs placebo at six-month timepoints, met statistical significance; 67% of wounds treated with VYJUVEK achieved the primary endpoint. Co intends to file a BLA with the FDA in the first half of 2022 and to submit a Marketing Authorization Application in Europe shortly afterward.
Waterdrop Inc (NYSE:WDH) improves off of Friday’s record lows on elevated volume. Co will report its Q3 results before the open tomorrow. Waterdrop Inc. provides online insurance brokerage services to match and connect users with related insurance products underwritten by insurance companies in the People’s Republic of China. It operates medical crowdfunding and mutual aid platforms. The company was founded in 2016 and is headquartered in Beijing, the People’s Republic of China.
NRX Pharmaceuticals Inc (NASDAQ:NRXP) today announced that completed an analysis to identify clinical evidence that indicates a “substantial improvement” following treatment with ZYESAMI in patients with Critical COVID-19 and Respiratory Failure over existing therapies, including remdesivir. Co has narrowed its requested Breakthrough Therapy Designation indication for ZYESAMI.
